NCT02231775View on ClinicalTrials.gov

Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 22, 2014

Primary Completion Date

April 1, 2027

Study Completion Date

April 1, 2027

Conditions
Stage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7
Interventions
DRUG

Dabrafenib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

DRUG

Trametinib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER